The stock of Revance Therapeutics Inc (NASDAQ:RVNC) is a huge mover today! The stock decreased 4.01% or $0.65 during the last trading session, hitting $15.56. About 142,995 shares traded hands. Revance Therapeutics Inc (NASDAQ:RVNC) has declined 11.19% since March 1, 2016 and is downtrending. It has underperformed by 23.40% the S&P500.
The move comes after 5 months negative chart setup for the $451.58M company. It was reported on Oct, 4 by Barchart.com. We have $13.38 PT which if reached, will make NASDAQ:RVNC worth $63.22M less.
Analysts await Revance Therapeutics Inc (NASDAQ:RVNC) to report earnings on November, 14. They expect $-0.90 earnings per share, down 11.11% or $0.09 from last year’s $-0.81 per share. After $-0.88 actual earnings per share reported by Revance Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.27% negative EPS growth.
Revance Therapeutics Inc (NASDAQ:RVNC) Ratings Coverage
Out of 4 analysts covering Revance Therapeutics (NASDAQ:RVNC), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Revance Therapeutics has been the topic of 5 analyst reports since August 22, 2015 according to StockzIntelligence Inc. The rating was initiated by Guggenheim with “Buy” on Monday, November 23. Brean Capital downgraded the stock to “Hold” rating in Tuesday, June 14 report. The stock of Revance Therapeutics Inc (NASDAQ:RVNC) has “Buy” rating given on Tuesday, June 14 by Suntrust Robinson. The rating was initiated by SunTrust on Wednesday, March 23 with “Buy”. Zacks downgraded the stock to “Hold” rating in Saturday, August 22 report.
According to Zacks Investment Research, “Revance Therapeutics, Inc. is a biopharmaceutical company which focuses on the development, manufacture and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications. The company’s technology platform includes TransMTS (R). Its lead product candidate consists of RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow’s feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. Revance Therapeutics, Inc. is based in Newark, United States.”
Insitutional Activity: The institutional sentiment increased to 1.39 in 2016 Q2. Its up 0.32, from 1.07 in 2016Q1. The ratio is positive, as 15 funds sold all Revance Therapeutics Inc shares owned while 16 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 28.60 million shares or 5.50% more from 27.11 million shares in 2016Q1.
Tekla Capital Management Limited Liability has 0.04% invested in the company for 75,000 shares. Teachers Advisors reported 32,072 shares or 0% of all its holdings. Iguana Healthcare Management Limited last reported 0.55% of its portfolio in the stock. Finemark Financial Bank & Tru has 0% invested in the company for 1,000 shares. Blackrock Investment Management Ltd Llc holds 78,313 shares or 0% of its portfolio. Canada Pension Plan Invest Board has 0.03% invested in the company for 610,300 shares. Moreover, Ladenburg Thalmann Fincl Services has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 12 shares. Jpmorgan Chase And, a New York-based fund reported 3.33M shares. Pointstate Ltd Partnership reported 250,000 shares or 0.07% of all its holdings. The New York-based Tiaa Cref Invest Mgmt Ltd Com has invested 0% in Revance Therapeutics Inc (NASDAQ:RVNC). Manufacturers Life The has 0% invested in the company for 14,920 shares. Credit Suisse Ag accumulated 0% or 24,852 shares. United Bank Va accumulated 77,177 shares or 1.04% of the stock. Essex Woodlands Ventures accumulated 15.74% or 4.59M shares. Rhenman And Partners Asset Mngmt Ab has 0.53% invested in the company for 220,000 shares.
Insider Transactions: Since April 11, 2016, the stock had 0 buys, and 3 insider sales for $53,540 net activity. Ruegg Curtis had sold 1,000 shares worth $18,250.
More recent Revance Therapeutics Inc (NASDAQ:RVNC) news were published by: Quotes.Wsj.com which released: “News Revance Therapeutics Inc.RVNC” on February 06, 2014. Also Businesswire.com published the news titled: “Revance Therapeutics to Release Second Quarter 2016 Financial Results Thursday …” on July 21, 2016. Seekingalpha.com‘s news article titled: “How Revance Is Misleading Investors About RT002” with publication date: November 20, 2015 was also an interesting one.
RVNC Company Profile
Revance Therapeutics, Inc., incorporated on August 10, 1999, is a biotechnology company. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. The Company’s TransMTS technology enables delivery of botulinum toxin type A through approximately two investigational drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. The Company’s botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. First, its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Second, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.